Invest in Teslake and Help Improve Spine Surgery
/Investing in Teslake presents an intriguing opportunity for retail investors.
Teslake, a cutting-edge medical device manufacturer, is developing a surgical robot to help correct spinal deformities. The company has also developed a metal alloy that is permanently antimicrobial. This groundbreaking technology has the potential to reduce the incidence of surgical infections, which currently afflict over 300,000 patients annually.
Teslake has raised over $2 million in funding.
Today, Teslake invites the everyday investor to join in its journey toward success. But, is investing in Teslake worth the risk? Keep reading and decide for yourself.
What Investors Need to Know About Teslake Stock
There are two reasons investors are interested in Teslake: Its spine robotics and antimicrobial alloy.
Teslake, founded in 2020, makes implants that surgeons use to fix injured or deformed spines. Its suite of products includes spinal implants and screws for correcting alignment, a special antimicrobial alloy that can be used to make surgical instruments, and a “team” of robots that can assist with the alignment surgery.
Teslake is currently in the process of developing a groundbreaking robotics system designed specifically for spinal deformity surgeries. Its innovative approach involves the creation of miniature robots that collaborate seamlessly with surgeons to rectify deformed spines during surgical procedures.
These robots function as a small team of tiny helpers, diligently ensuring the precise alignment of the spine to its natural and correct position while the surgeon works around them.
These compact mini-robots perform a critical role by essentially providing surgeons with an invaluable "extra set of hands." This robotic assistance corrects spinal deformities before the placement of rods, enhancing the surgical precision and outcome.
Furthermore, Teslake has successfully mastered the processing of a unique metal alloy known as Guardinium™ Alloy. This breakthrough allows the manufacturing of surgical instruments capable of eradicating bacteria, viruses, or fungi upon contact. The introduction of Guardinium™ Alloy is poised to replace conventional stainless steel used in surgical instrument products, marking a significant advancement within the medical field.
Teslake investors like the two-for-one potential of the technology as it applies to more market verticals for expansion.
Why Guardium Alloy Excites Teslake Investors
Guardinium™ Alloy, represents a groundbreaking solution poised to significantly reduce infection rates in surgical procedures. With as many as 300,000 surgical site infections reported annually, the versatility of Guardinium™ Alloy extends its application to virtually any surgical or medical scenario where infection poses a concern.
Investing in Teslake is the only way for investors to share in the growth of this new material.
What sets Teslake apart is its unique expertise in refining the processing of Guardinium™ Alloy to attain extraordinary corrosion resistance, biocompatibility, and mechanical strength, providing performance similar to austenitic stainless steel.
The material has the remarkable ability to coax microbes to donate electrons, leading to the rapid deterioration of DNA and cell proteins within minutes. This swift and effective process results in the rapid collapse of the infectious population, rendering the microbe inactive within a matter of minutes or hours. Teslake’s innovative approach, if proven out in real-world clinical studies, could be nothing short of a game-changer in the battle against surgical infections.
Why Investors Are Bullish On Teslake Stock
Teslake is at the forefront of addressing three critical medical challenges:
1. Manual Techniques: Traditional spinal deformity surgeries rely heavily on manual and physically demanding procedures. Teslake's pioneering robotics are leading the charge in automating segmental spine correction during surgery.
2. Screw Loosening: Current methods involve the risk of screws loosening during the spinal correction process. Surgeons typically apply significant force to a titanium rod, potentially compromising the integrity of the screws. Teslake's robotic technology enables precise correction of the spine without undue force, reducing the likelihood of screw loosening. Additionally, it possesses the capability to detect any loosening of screws within the bone, potentially enhancing patient safety. This innovation also eliminates the need for a second surgeon to assist, streamlining the procedure.
3. Infections: Infections post-surgery are distressingly prevalent, affecting 5-15% of spinal deformity surgery patients. This issue imposes a substantial financial burden, with up to 300,000 surgical site infections annually, costing between $3.5 billion to $10 billion annually.
How Teslake Can Reward Early Shareholders
Teslake has already proven there is growing demand for its innovations. But investors are also looking for long-term growth potential.
In a remarkably brief span of under three years, Teslake has successfully implanted more than 1,000 screws, underscoring its rapid progress and impact in the medical field. Teslake has raised over $2 million in funding, bringing their valuation to an impressive $30 million.
Notably, Teslake has garnered the trust and collaboration of esteemed surgeons affiliated with prestigious institutions such as Stanford, The Cleveland Clinic Foundation, The Mayo Clinic Network, The University of Chicago, and Georgetown. This network of partnerships and endorsements underscores the growing credibility and efficacy of Teslake's products within the medical community.
Looking ahead, Teslake's team has devised a comprehensive four-step growth plan that will guide its trajectory over the next few years.
The first step is to increase the size of the sales team. Currently, the CEO, Stephen Foti, is the only sales team member.
The second step is to add a marketing department to start advertising & marketing their products. Up until now, all of the marketing efforts have been word of mouth with zero advertising.
The third step is to increase the inventory of existing FDA-approved products.
The fourth step is to expand its research and development (R&D) on Guardinium™ Alloy & get onto the podium at major surgical conferences. In doing so, the product will gain further credibility within the medical community.
Is Teslake a Good Investment?
If you’re wondering, “should I invest in Teslake?”, at Money & Mimosas we encourage you to ask yourself three questions:
What are the potential roadblocks?
What is the potential growth or upside?
How does this align with my values and/or overall investment strategy?
The biggest potential roadblock we see for Teslake is the challenge of widespread adoption. While the company's innovations occupy a unique position, signifying a blue ocean of little to no competition, they face the formidable task of competing with the entrenched status quo. Therefore, it will be critical for the team to significantly elevate its brand awareness strategy and execute a robust marketing campaign to usher in a new era of acceptance and appreciation for its pioneering solutions.
That being said, Teslake has demonstrated that the medical community possesses a strong appetite for innovative tools, as hospitals and surgeons actively seek ways to mitigate healthcare-associated infections. Teslake's Guardinium™ Alloy could be a major solution to this pressing problem.
Additionally, it's crucial to note that Guardinium™ Alloy is safeguarded as a proprietary trade secret, adding another layer of protection to Teslake's groundbreaking technology. The company has taken proactive steps by filing for FDA 510(k) approval, which includes comprehensive biocompatibility data, effectively erecting a regulatory barrier to deter potential competitors from replicating its innovative product.
Another upside for Teslake stock is the quality of Teslake’s team. Stephen Foti, the CEO, has over 20 years in orthopedic sales leadership resulting in $100M+ annual territory sales revenue. Lukas, the team’s President, has been developing spinal implant & instrument products for 28 years. He has run 5 FDA IDE studies, has numerous patents in the field, and prior experience running start-ups in the space.
How to Invest in Teslake Stock
The terms are on the investment page. The minimum investment is $1,009 and purchasing is open to all investors. You don’t have to be an accredited investor to invest in Teslake.
The process of investing is really easy. You head over to the Teslake investment page and click the ‘Invest Now’ button. From there, the website will walk you through the seamless process of becoming an investor in Teslake.
